1. In vivo targeting of protein antigens to dendritic cells using anti-DEC-205 single chain antibody improves HIV Gag specific CD4 + T cell responses protecting from airway challenge with recombinant vaccinia-gag virus.
- Author
-
Ngu LN, Nji NN, Ambada GE, Sagnia B, Sake CN, Tchadji JC, Njambe Priso GD, Lissom A, Tchouangueu TF, Manga Tebit D, Waffo AB, Park CG, Steinman RM, Überla K, and Nchinda GW
- Subjects
- AIDS Vaccines administration & dosage, Adjuvants, Immunologic, Animals, CD4-Positive T-Lymphocytes metabolism, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes metabolism, CHO Cells, Cell Line, Cricetulus, Dendritic Cells metabolism, Disease Models, Animal, Female, HIV immunology, HIV Infections immunology, HIV Infections metabolism, HIV Infections prevention & control, Humans, Immunization, Immunogenicity, Vaccine immunology, Lymphocyte Activation immunology, Mice, Mice, Knockout, Single-Chain Antibodies pharmacology, T-Cell Antigen Receptor Specificity immunology, AIDS Vaccines immunology, Antigens immunology, CD4-Positive T-Lymphocytes immunology, CD4-Positive T-Lymphocytes virology, Dendritic Cells immunology, Single-Chain Antibodies immunology, gag Gene Products, Human Immunodeficiency Virus immunology
- Abstract
Introduction: Targeting antigens to dendritic cells (DCs) in vivo via a DC-restricted endocytic receptor, DEC205, has been validated to enhance immunity in several vaccine platforms. Particularly atttractive is selected delivery of proteins to DCs in vivo because it enables proteins to be more immunogenic and provides a cheaper and effective way for repeated immunizations., Methods: In this study, we tested the efficacy of a single chain antibody to DEC205 (scDEC) to deliver protein antigens selectively to DCs in vivo and to induce protective immunity., Results: In comparison to soluble Ovalbumin (OVA) antigen, when recombinant scDEC:OVA protein was injected subcutaneously (s.c.) into mice, the OVA protein was selectively presented by DCs to both TCR transgenic CD8
+ and CD4+ T cells approximately 500 and 100 times more efficient than soluble OVA, respectively, and could persist for seven days following s.c. injection of the scDEC205:OVA. Similarly selective targeting of HIV Gag P24 to DCs in vivo using scDEC-Gag protein plus polyICLC vaccine resulted in strong, long lasting, polyfuntional CD4+ T cells in mice which were protective against airway challenge by a recombinant vaccinia-gag virus., Conclusion: Thus targeting protein antigens to DCs using scDEC can be used either alone or in combination with other strategies for effective immunization., (© 2017 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd.)- Published
- 2019
- Full Text
- View/download PDF